Futura Medical PLC Director / PCA Shareholding (9911P)
16 October 2019 - 3:42AM
UK Regulatory
TIDMFUM
RNS Number : 9911P
Futura Medical PLC
15 October 2019
Director / PCA Shareholding
15 October 2019
Futura Medical Plc (AIM: FUM) ("Futura" or "the Company"), a
pharmaceutical company developing a portfolio of innovative
products based on its proprietary, transdermal DermaSys(R) drug
delivery technology and currently focused on sexual health and
pain, today received notification that on 14 October 2019,
Charlotte Barder, a person closely associated (PCA) with James
Barder, the Company's CEO, sold 66,500 ordinary shares of 0.2 pence
in the Company ("Ordinary Shares") at a price of 28.5 pence per
share and repurchased 66,500 Ordinary Shares at a price of 28.55
pence per share. These trades were carried out as part of a "Bed
and ISA" process, allowing Charlotte to move her existing
shareholding into an ISA.
Following these trades James Barder's beneficial holding remains
unchanged at 968,472 ordinary shares with an aggregate beneficial
and non-beneficial holding of 1,085,972 Ordinary Shares,
representing 0.53 per cent. of the current total voting rights of
the Company. James Barder also has options over 1,750,000 Ordinary
Shares.
Further details are contained within the notification below,
made in accordance with Article 19 of the EU Market Abuse
Regulation 596/2014.
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal Dermasys(R) drug delivery technology.
These products are optimised for clinical efficacy, safety,
administration and patient convenience and are developed for the
prescription and consumer healthcare markets as appropriate.
Current therapeutic areas are sexual health, including erectile
dysfunction, and pain relief. Development and commercialisation
strategies are designed to maximise product differentiation and
value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as
"FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study of
MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment
of erectile dysfunction with an open label extension. FM57 is
progressing on track, with headline data expected by the end of
2019.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Charlotte Barder
-------------------------------- ------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status PCA of James Barder, CEO
-------------------------------- ------------------------------------------
b) Initial notification Initial
/Amendment
-------------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Futura Medical Plc
-------------------------------- ------------------------------------------
b) LEI 21380053QLT46UNV2303
-------------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.2 pence
financial instrument,
type of instrument
Identification code ISIN: GB0033278473
b) Nature of the transaction Transfer of 66,500 Ordinary Shares,
via sale and repurchase
-------------------------------- ------------------------------------------
c) Price(s) and volume(s)
------------ ------------------------
Price(s) Volume(s)
------------ ------------------------
28.55p 66,500 (sale)
------------ ------------------------
28.5p 66,500 (purchase)
------------ ------------------------
d) Aggregated information
- Aggregated volume 66,500 (sale)
- Price 28.55p
- Total GBP18,985.75
- Aggregated volume 66,500 (purchase)
- Price 28.5p
- Total GBP18,952.50
e) Date of the transaction 14 October 2019
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
-------------------------------- ------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHQELFFKBFXFBZ
(END) Dow Jones Newswires
October 15, 2019 12:42 ET (16:42 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2024 to May 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From May 2023 to May 2024